Nirvana Life Sciences Inc.

C$0.05As of Sun 8 Nov 2026, 12:00 UTC
CSE:NIRV-XHealthcare
Country Canada
PE (Fwd) •••
TSR 5Y CAGR (63.50%)
Div yield —
ROE —
Pharmaceutical Preparations
Beta (5Y) (0.93)
PE TTM —
TSR TTM (64.29%)
Mkt cap C$1.146M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.0496
(0.75%)
76.41%
Hold 1|10|6|11|12
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
23.18%
24.70%
24.74%
27.80%
Revenue$M
0.067
0.066
0.067
0.068
(2.38%)
(3.31%)
(1.05%)
2.35%
Peers (US$0.811M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.836
5.297
3.946
EBIT/Intx
1.317
0.358
0.243
Own earn%
(337.73)
(34.03)
(56.73)
Sh yield%
24.02
54.94
52.72
Owners
Insiders/Inst%
10.72
35.42
Short interest%
3.42
SBC / revenue%
2.09
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
0–4
$1 testx
—
Incr. ROIC%
3